ICLR vs IQV: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ICLR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ICLR and IQV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ICLR and IQV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

ICON plc (NASDAQ: ICLR) is a Dublin-headquartered contract research organization that provides outsourced clinical development services to pharmaceutical, biotechnology, medical device, and government clients. As of March 2026 it had roughly 40,350 employees across about 97 locations in 55 countries, and it manages studies spanning compound selection through Phase I to Phase IV trials. Revenue is booked against a large backlog, so bookings and book-to-bill ratios are watched as closely as reported sales.

Full ICLR guide

IQVIA Holdings is a healthcare-focused data, analytics, and clinical-research company formed in 2016 from the merger of Quintiles (a large CRO) and IMS Health (a pharmaceutical-data provider). It operates in three segments: Technology & Analytics Solutions, which sells prescription and market data, real-world evidence, and commercial software to drug and device makers; Research & Development Solutions, its clinical research organization arm that designs and runs clinical trials on behalf of pharma and biotech sponsors; and Contract Sales & Medical Solutions. IQVIA makes money from long-duration trial contracts, recurring data and software subscriptions, and consulting, serving essentially all of the top 20 global pharmaceutical companies.

Full IQV guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ICLR drivers: Backlog and bookings momentum; Structural CRO outsourcing growth.
• IQV drivers: Record backlog and bookings momentum; Proprietary data and analytics moat.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: ICON faces cyclical risk from pharmaceutical reprioritization, trial cancellations, and swings in biotech funding, all of which can slow bookings conversion. For IQV, iQVIA's demand is tied to pharma and biotech R&D budgets, which are cyclical: biopharma funding fell about 20 percent in 2025 to roughly $82 billion as IPOs hit a decade low, and prolonged funding weakness can slow trial starts, RFP flow, and bookings.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ICLR if you believe its drivers more; IQV if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ICLR and IQV guides.

ICLR. ICON reaffirmed full-year 2026 guidance of roughly $7.85 billion to $8.15 billion in revenue and about $10.00 to $11.00 in adjusted diluted EPS. The low-teens trailing multiple reflects softer near-term margins and demand, while backlog of around $22.7 billion underpins forward visibility. Figures are approximate and drawn from company filings and market data.

IQV. IQVIA reported full-year 2025 revenue of about $16.3 billion with adjusted diluted EPS near $11.92, and issued 2026 revenue guidance of roughly $17.15 to $17.35 billion alongside adjusted EPS guidance of about $12.55 to $12.85. At a mid-2026 share price near $208 and a market cap around $35 billion, the stock traded at a P/E in the high teens to about 20x, a valuation that has compressed from prior years. The record backlog of about $34.2 billion provides visibility, but the pace of backlog-to-revenue conversion and biotech funding trends drive how much of that guidance is realized.

Headline figures (approximate, July 2026): ICLR shows market cap ~$8.9B, revenue (ttm) ~$8.1B, q1 2026 revenue ~$2.03B, q1 2026 adjusted eps ~$2.50; IQV shows revenue (fy2025) ~$16.3 billion, adjusted diluted eps (fy2025) ~$11.92, adjusted ebitda (fy2025) ~$3.8 billion, backlog (q1 2026) ~$34.2 billion.

ICLR and IQV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ICLR and IQV exposure against your real portfolio. It is not an investment adviser.